Inhibition of SGK-1 as a Novel Means to Treat Autoimmune Disease and Enhance Anti-pathogen and Anti-tumor Immunity

Case ID:
C11550

C11550: Novel Target for Treatment of Autoimmune Diseases

Novelty:

Inhibition of this novel target has the potential to treat autoimmune diseases, as well as enhancing immunity against pathogen infections and tumor formation.

Value Proposition:

Currently, most immunosuppressive therapies non-specifically inhibit the immune system and leave the body susceptible to infection. Inhibition of this novel target addresses this perilous side effect by directly targeting the effectors responsible for human immune response and promotion of autoimmune diseases, while leaving the rest of the immune system intact to fight infections through enhanced cellular immunity pathways. Other advantages include:

• Novel target for drug development for patients with Th2 mediated autoimmune diseases like asthma, lupus etc..
• Drug development applications can be expanded to a range of non-viral and viral diseases.
• Implications in promoting anti-tumor immunity and improved efficacy of vaccines.
• Proof of concept studies in mice asthma model.

Technical Details:

Johns Hopkins University researchers have discovered a novel target which when inhibited selectively addresses Th2-mediated autoimmune disorders while enhancing Th1 mediated immune response to pathogen and tumor activity. The target is one of the many downstream components involved in the mammalian target of rapamycin (mTOR) pathway, a master regulator of T-cell differentiation. Knockout mice were engineered in which the protein was specifically deleted in CD4+ and CD8+ T cells. The results of biochemical experiments indicate that these cells adopt a Th1 phenotype even under Th2 skewing conditions. The cells inability to adopt a Th2 phenotype made the knockout mice resistant to induced allergic asthma. Additional studies suggest that these mice have increased anti-viral and anti-tumor immunity.

Looking for Partners:

To commercialize the technology by developing inhibitors to the novel target for long term treatment of asthma, as a combination with vaccines to boost their efficacy to prevent infection and promote anti-tumor immunity

Stage of Development:

Pre-Clinical

Data Availability:

Under NDA/CDA

Publications/Associated Cases:

Not available at this time

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Compositions and Methods for Treatin Autoimmunity, Infections, and Cancer DIV: Divisional United States 15/062,576 11,103,486 3/7/2016 8/31/2021 10/22/2033 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum